In addition, HFD treatment resulted in an increase in the blood glucose levels and AUC during IPGTT and IPITT, which were then declined by Asprosin absence, revealing that Asprosin depletion improved glucose tolerance and insulin sensitivity in NAFLD. Here, FBN1 is linked to metabolic dysfunction-associated steatotic liver disease.